𝔖 Bobbio Scriptorium

✦ LIBER ✦

Peg-interferon alfa-2B 1.5μG/KG plus ribavirin 800–1400mg/day for 24 weeks in patients with HCV 2 or 3

Book ID: 118689387
Publisher: John Wiley and Sons
Year: 2003
Tongue: English
Weight: 132 KB
Volume: 38
Category: Article
ISSN: 0270-9139
DOI: 10.1053/s0270-9139(03)81806-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

335 Interim results of a randomized tria

335 Interim results of a randomized trial of 1.5μG/ KG vs. 3.0 μG/KG pegylated interferon alfa 2-B PEG-intron(R) (PEG) plus ribavirin (RBV) for naïve chronic hepatitis C patients and 3.0μG/KG PEG plus RBV for non-responders (NR) and relapsers (R) to previous therapy. (The target trial)

✍ Calvin L. White; Peter F. Malet; Corinne L. Wentworth; Veronica L. Cantu; Tamera 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 157 KB

Peginterferon A-2B 1 MCG/kg dose plus ri

Peginterferon A-2B 1 MCG/kg dose plus ribavirin 800–1200MG for 24–48 weeks, according to genotype, in naive patients with chronic hepatitis C

✍ M. Basso; A. Grasso; G. Percario; E. Azzola; S. Artioli; N. Pelli; S. Blanchi; F 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 118 KB

Comparison of two PEG-interferon alpha-2

Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 μg/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up to moderate fibrosis

✍ B. Meyer-Wyss; P. Rich; Hp Egger; B. Helbling; B. Müllhaupt; C. Rammert; J.-J. G 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 220 KB

642 INDIVIDUALIZED TREATMENT DURATION WI

642 INDIVIDUALIZED TREATMENT DURATION WITH PEGINTERFERON-ALFA-2B AND RIBAVIRIN FOR 24, 30 OR 36 WEEKS IN HCV GENOTYPE1-INFECTED PATIENTS WITH UNDETECTABLE HCV-RNA EARLY DURING THERAPY (INDIV-2 STUDY)

✍ C. Sarrazin; S. Schwendy; B. Möller; N. Dikopoulos; P. Buggisch; J. Encke; G. Te 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 49 KB

PEG12000-IFN alfa 2B 0.5 mcg/kg + ribavi

PEG12000-IFN alfa 2B 0.5 mcg/kg + ribavirin 800 mg/day vs. PEG12000-IFN alfa 2B 1.5 mcg/kg + ribavirin 800 mg/day for 48 weeks for treatment of patients with hepatitis C who failed or relapsed after treatment with combination therapy (rebetron)-interim results: Douglas D Dalke, Gastroenterology Specialties, Lincoln, NE; Jeremiah Donovan, Creighton University, Omaha, NE; John Goff, Rocky Mountain Gastroenterology, Denver, CO; Howard Monsour, Gastroenterology & Liver Assoc, Houston, TX; Terry Box, Mountain West Gastroenterology, Salt Lake City, UT; Andre Triebling, Arapahoe Gastroenterology, Denver, CO; Douglas Brouillette, Internal Medicine Assoc, Omaha, NE; Robert Levine, Boulder Medical Ctr, Boulder, CO; Lawrence Kim, South Denver Gastroenterology, Englewood, CO; Mark Malliard, Univ of NE Dept of Hepatology, Omaha, NE

📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 196 KB